

## GeNeuro: financial information and business update for the third quarter 2022

- Solid financial situation and strong visibility:
  - Cash position of €9.6 million
  - Operations funded until end 2023

**Geneva, Switzerland, October 24, 2022, 7:30am CEST** – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), today reported on its 2022 third quarter cash position and issued a business update.

### 2022 Third-quarter financial information

At September 30, 2022, GeNeuro had €9.6 million in cash. As announced in the interim financial report for the six months ended June 30, 2022, the available cash resources provide GeNeuro with financial visibility until end of 2023, covering all planned activities.

The cash consumption related to GeNeuro's operating and investing activities in Q3 2022 was €1.4 million, slightly up from the average of €1.25 million for the first two quarters as a result of the ramp-up of the long-COVID Phase 2 clinical trial which has started recruiting patients. During this third quarter, as already mentioned in the interim half-year report, the Company received the second installment of €2 million from the Swiss Federal Office for Public Health (FOPH) subsidy for the long-COVID Phase 2 clinical trial. This Q3 2022 cash consumption was in line with the Company's expectations; full-year cash consumption remains estimated at approximately €6 million on a net basis, i.e. after taking into account the FOPH subsidy for the long-COVID Phase 2 clinical trial.

### Key developments during the quarter

- On August 30, 2022, the Company announced the joint publications in the leading scientific journal "Annals of Neurology" of the results of the collaboration between GeNeuro and the National Institute of Neurological Disorders and Stroke (NINDS), accessible [here](#).

### About GeNeuro

GeNeuro's mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA.

GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France. It has rights to 17 patent families protecting its technology.

For more information, visit: [www.geneuro.com](http://www.geneuro.com)



### Contacts

**GeNeuro**

Jesús Martin-Garcia  
Chairman and CEO  
+41 22 552 4800

[investors@geneuro.com](mailto:investors@geneuro.com)

**NewCap (France)**

Mathilde Bohin/  
Louis-Victor Delouvrier  
(investors)  
+33 1 44 71 98 52

Arthur Rouillé (media)  
+33 1 44 71 94 98  
[geneuro@newcap.eu](mailto:geneuro@newcap.eu)

**RooneyPartners (US)**

Jeanene Timberlake (media)  
+1 646 770 8858

[jtimmerlake@rooneypartners.com](mailto:jtimmerlake@rooneypartners.com)

**Disclaimer**

This press release contains certain forward - looking statements and estimates concerning GeNeuro's financial condition, operating results, strategy, projects and future performance and the markets in which it operates. Such forward-looking statements and estimates may be identified by words, such as "anticipate," "believe," "can," "could," "estimate," "expect," "intend," "is designed to," "may," "might," "plan," "potential," "predict," "objective," "should," or the negative of these and similar expressions. They incorporate all topics that are not historical facts. Forward looking statements, forecasts and estimates are based on management's current assumptions and assessment of risks, uncertainties and other factors, known and unknown, which were deemed to be reasonable at the time they were made but which may turn out to be incorrect. Events and outcomes are difficult to predict and depend on factors beyond the company's control. Consequently, the actual results, financial condition, performances and/or achievements of GeNeuro or of the industry may turn out to differ materially from the future results, performances or achievements expressed or implied by these statements, forecasts and estimates. Owing to these uncertainties, no representation is made as to the correctness or fairness of these forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates speak only as of the date on which they are made, and GeNeuro undertakes no obligation to update or revise any of them, whether as a result of new information, future events or otherwise, except as required by law.